Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Choroidal Neovascularization Clear all
Completed Not applicable Interventional
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Proton radiation
Radiation
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced May 22, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
"Wet" Age-Related Macular Degeneration
Interventions
Squalamine Lactate
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
29
States / cities
Beverly Hills, California • Louisville, Colorado • Boynton Beach, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced May 22, 2026, 5:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Drug: GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
Intravitreal aflibercept injection 2.0mg
Drug
Lead sponsor
Gregg T. Kokame, MD
Other
Eligibility
25 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
‘Aiea, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced May 22, 2026, 5:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
NG101 AAV gene therapy
Genetic
Lead sponsor
Elisigen, Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Cincinnati, Ohio • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 22, 2026, 5:24 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Macular Degeneration
Interventions
NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
Drug
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced May 22, 2026, 5:24 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Neovascular Polypoidal Choroidal Vasculopathy
Interventions
Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced May 22, 2026, 5:24 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Macular Degeneration
Interventions
rhuFab V2 (ranibizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Macular Degeneration
Interventions
TAC-PF, Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 5:24 AM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
episcleral brachytherapy
Radiation
Lead sponsor
Salutaris Medical Devices, Inc.
Industry
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
‘Aiea, Hawaii • Oak Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced May 22, 2026, 5:24 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Maculopathy, Age-Related, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Beverly Hills, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2009 · Synced May 22, 2026, 5:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
The Retina Center of St. Louis County, PC
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced May 22, 2026, 5:24 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Ocular Histoplasmosis
Interventions
aflibercept
Drug
Lead sponsor
John Kitchens, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Augusta, Georgia • Lexington, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced May 22, 2026, 5:24 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Choroidal Neovascularization
Interventions
Ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced May 22, 2026, 5:24 AM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Ocular Brachytherapy
Device
Lead sponsor
Theragenics Corporation
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Atlanta, Georgia • Augusta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 5:24 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization
Interventions
ForeseeHome
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Palm Beach Gardens, Florida • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced May 22, 2026, 5:24 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
9
States / cities
Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
1,775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced May 22, 2026, 5:24 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Fluocinolone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 5:24 AM EDT